Selank - Beligas Pharmaceuticals

Recent research highlights Selank's promising role in modulating stress-induced immune responses, particularly through its effects on cytokine levels under chronic social stress conditions. Typically, inflammatory cytokines like IL-1β and IL-6 are produced in response to immune challenges; however, chronic stress has also been shown to trigger these pro-inflammatory markers, contributing to systemic inflammation and potentially impacting neurological function. In studies with rats exposed to controlled social stress, Selank administration effectively reduced the levels of pro-inflammatory cytokines IL-1β and IL-6, both key markers of immune activation during stress. Additionally, Selank significantly decreased TNF-α and TGF-β1, which are linked to stress-induced immune changes, while restoring levels of IL-4, an anti-inflammatory cytokine. This balanced cytokine profile suggests Selank’s ability to stabilize immune response under stress, preventing an exaggerated inflammatory response. During the experiment, rats exposed to social stress experienced a marked increase in pro-inflammatory markers, which was effectively mitigated with daily Selank doses, bringing cytokine levels closer to those in non-stressed control animals. These findings suggest Selank could serve as a powerful therapeutic tool in treating stress-related immune dysregulation, supporting its potential use in neuroprotective and anti-inflammatory therapies aimed at preserving immune health under chronic stress conditions.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Selank by Beligas Pharmaceuticals, consult with your doctor or healthcare professional.